Acute phase reactants. II. Serum hexosamines in patients with rheumatic fever and related diseases (Q41049547)

26 September 2017

Acute phase reactants. II. Serum hexosamines in patients with rheumatic fever and related diseases (English)

1 reference

26 September 2017

0 references

KELLEY VC

1

1 reference

PubMed ID

14918031

26 September 2017

language of work or name

English

0 references

publication date

1 April 1952

1 reference

The Journal of Pediatrics

26 September 2017

1 reference

26 September 2017

40

1 reference

26 September 2017

4

1 reference

26 September 2017

413-422

1 reference

THE CONCENTRATION OF GLUCOSAMINE IN NORMAL AND PATHOLOGICAL SERA.

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

Plasma hexosamine levels in acute rheumatic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

The effect of adrenocorticotropic hormone and cortisone on the serum hexosamine level in acute disseminated lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

Serum polysaccharide level in the normal state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

A colorimetric method for the determination of glucosamine and chondrosamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

STUDIES ON THE MUCOPROTEINS OF HUMAN PLASMA. I. DETERMINATION AND ISOLATION.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

Metabolism of Hyaluronic Acid in Relation to Rheumatic Diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

The pathogenesis of lupus erythematosus and allied conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

THE ROLE OF THE MUCOID POLYSACCHARIDE (HYALURONIC ACID) IN THE VIRULENCE OF GROUP A HEMOLYTIC STREPTOCOCCI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

THE EFFECT OF EXTRACTS OF CERTAIN ORGANS FROM NORMAL AND IMMUNIZED ANIMALS ON THE INFECTING POWER OF VACCINE VIRUS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

STUDIES ON A CERTAIN SPREADING FACTOR EXISTING IN BACTERIA AND ITS SIGNIFICANCE FOR BACTERIAL INVASIVENESS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

A SPREADING FACTOR IN CERTAIN SNAKE VENOMS AND ITS RELATION TO THEIR MODE OF ACTION.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

THE INFLUENCE OF TESTICLE EXTRACT ON THE INTRADERMAL SPREAD OF INJECTED FLUIDS AND PARTICLES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

Studies on diffusing factors. Active preparations from mammalian testicle and their biological assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

Studies on diffusing factors: The hyaluronidase activity of testicular extracts, bacterial culture filtrates and other agents that increase tissue permeability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

The biological significance of hyaluronic acid and hyaluronidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

HYALURONIDASES OF BACTERIAL AND ANIMAL ORIGIN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

On the occurrence in human serum of an inhibitory substance to hyaluronidase produced by a strain of hemolytic streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

ANTIHYALURONIDASE STUDIES OF SERA FROM PATIENTS WITH RHEUMATIC FEVER, STREPTOCOCCAL INFECTIONS, AND MISCELLANEOUS NON-STREPTOCOCCAL DISEASES.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

Hyaluronidase inhibitors in body fluids in normal and disease states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

Mucolytic enzyme systems; inhibition of hyaluronidase by serum in infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

Mucolytic enzyme systems; nonspecific hyaluronidase inhibitor in rheumatic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

Mucolytic enzyme systems. XI. Hyaluronidase inhibitor and serum mucoproteins in patients with lipoid nephrosis and acute glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

Influence of hyaluronidase and steroids on permeability of synovial membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2852%2980204-5

10.1016/S0022-3476(52)80204-5

7 January 2021

Identifiers

DOI

1 reference

26 September 2017

1 reference

PubMed ID

14918031